Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6291 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867005293881196544 |
|---|---|
| author | Tamara Cubiella Lucía Celada Jaime San‐Juan‐Guardado Raúl Rodríguez‐Aguilar Álvaro Suárez‐Priede María Poch Francisco Dominguez Iván Fernández‐Vega Pedro Montero‐Pavón Mario F Fraga Yoichiro Nakatani So Takata Shinichi Yachida Nuria Valdés María‐Dolores Chiara |
| author_facet | Tamara Cubiella Lucía Celada Jaime San‐Juan‐Guardado Raúl Rodríguez‐Aguilar Álvaro Suárez‐Priede María Poch Francisco Dominguez Iván Fernández‐Vega Pedro Montero‐Pavón Mario F Fraga Yoichiro Nakatani So Takata Shinichi Yachida Nuria Valdés María‐Dolores Chiara Tamara Cubiella Lucía Celada Jaime San‐Juan‐Guardado Raúl Rodríguez‐Aguilar Álvaro Suárez‐Priede María Poch Francisco Dominguez Iván Fernández‐Vega Pedro Montero‐Pavón Mario F Fraga Yoichiro Nakatani So Takata Shinichi Yachida Nuria Valdés María‐Dolores Chiara |
| collection | Wiley Open Access |
| contents | PCDHGC3 hypermethylation as a potential biomarker of intestinal neuroendocrine carcinomas Tamara Cubiella Lucía Celada Jaime San‐Juan‐Guardado Raúl Rodríguez‐Aguilar Álvaro Suárez‐Priede María Poch Francisco Dominguez Iván Fernández‐Vega Pedro Montero‐Pavón Mario F Fraga Yoichiro Nakatani So Takata Shinichi Yachida Nuria Valdés María‐Dolores Chiara The Journal of Pathology AbstractNeuroendocrine neoplasms (NENs) encompass tumors arising from neuroendocrine cells in various organs, including the gastrointestinal tract, pancreas, adrenal gland, and paraganglia. Despite advancements, accurately predicting the aggressiveness of gastroenteropancreatic (GEP) NENs based solely on pathological data remains challenging, thereby limiting optimal clinical management. Our previous research unveiled a crucial link between hypermethylation of the protocadherin PCDHGC3 gene and neuroendocrine tumors originating from the paraganglia and adrenal medulla. This epigenetic alteration was associated with increased metastatic potential and succinate dehydrogenase complex (SDH) dysfunction. Expanding upon this discovery, the current study explored PCDHGC3 gene methylation within the context of GEP‐NENs in a cohort comprising 34 cases. We uncovered promoter hypermethylation of PCDHGC3 in 29% of GEP‐NENs, with a significantly higher prevalence in gastrointestinal (GI) neuroendocrine carcinomas (NECs) compared with both pancreatic (Pan) NECs and neuroendocrine tumors (NETs) of GI and Pan origin. Importantly, these findings were validated in one of the largest multi‐center GEP‐NEN cohorts. Mechanistic analysis revealed that PCDHGC3 hypermethylation was not associated with SDH mutations or protein loss, indicating an SDH‐independent epigenetic mechanism. Clinically, PCDHGC3 hypermethylation emerged as a significant prognostic factor, correlating with reduced overall survival rates in both patient cohorts. Significantly, whereas PCDHGC3 hypermethylation exhibited a strong correlation with TP53 somatic mutations, a hallmark of NEC, its predictive value surpassed that of TP53 mutations, with an area under the curve (AUC) of 0.95 (95% CI 0.83–1.0) for discriminating GI‐NECs from GI‐NETs, highlighting its superior predictive performance. In conclusion, our findings position PCDHGC3 methylation status as a promising molecular biomarker for effectively stratifying patients with GI‐NENs. This discovery has the potential to advance patient care by enabling more precise risk assessments and tailored treatment strategies. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. 10.1002/path.6291 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/path.6291 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_path_6291 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | PCDHGC3 hypermethylation as a potential biomarker of intestinal neuroendocrine carcinomas Tamara Cubiella Lucía Celada Jaime San‐Juan‐Guardado Raúl Rodríguez‐Aguilar Álvaro Suárez‐Priede María Poch Francisco Dominguez Iván Fernández‐Vega Pedro Montero‐Pavón Mario F Fraga Yoichiro Nakatani So Takata Shinichi Yachida Nuria Valdés María‐Dolores Chiara The Journal of Pathology PCDHGC3 hypermethylation as a potential biomarker of intestinal neuroendocrine carcinomas Tamara Cubiella Lucía Celada Jaime San‐Juan‐Guardado Raúl Rodríguez‐Aguilar Álvaro Suárez‐Priede María Poch Francisco Dominguez Iván Fernández‐Vega Pedro Montero‐Pavón Mario F Fraga Yoichiro Nakatani So Takata Shinichi Yachida Nuria Valdés María‐Dolores Chiara The Journal of Pathology AbstractNeuroendocrine neoplasms (NENs) encompass tumors arising from neuroendocrine cells in various organs, including the gastrointestinal tract, pancreas, adrenal gland, and paraganglia. Despite advancements, accurately predicting the aggressiveness of gastroenteropancreatic (GEP) NENs based solely on pathological data remains challenging, thereby limiting optimal clinical management. Our previous research unveiled a crucial link between hypermethylation of the protocadherin PCDHGC3 gene and neuroendocrine tumors originating from the paraganglia and adrenal medulla. This epigenetic alteration was associated with increased metastatic potential and succinate dehydrogenase complex (SDH) dysfunction. Expanding upon this discovery, the current study explored PCDHGC3 gene methylation within the context of GEP‐NENs in a cohort comprising 34 cases. We uncovered promoter hypermethylation of PCDHGC3 in 29% of GEP‐NENs, with a significantly higher prevalence in gastrointestinal (GI) neuroendocrine carcinomas (NECs) compared with both pancreatic (Pan) NECs and neuroendocrine tumors (NETs) of GI and Pan origin. Importantly, these findings were validated in one of the largest multi‐center GEP‐NEN cohorts. Mechanistic analysis revealed that PCDHGC3 hypermethylation was not associated with SDH mutations or protein loss, indicating an SDH‐independent epigenetic mechanism. Clinically, PCDHGC3 hypermethylation emerged as a significant prognostic factor, correlating with reduced overall survival rates in both patient cohorts. Significantly, whereas PCDHGC3 hypermethylation exhibited a strong correlation with TP53 somatic mutations, a hallmark of NEC, its predictive value surpassed that of TP53 mutations, with an area under the curve (AUC) of 0.95 (95% CI 0.83–1.0) for discriminating GI‐NECs from GI‐NETs, highlighting its superior predictive performance. In conclusion, our findings position PCDHGC3 methylation status as a promising molecular biomarker for effectively stratifying patients with GI‐NENs. This discovery has the potential to advance patient care by enabling more precise risk assessments and tailored treatment strategies. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. 10.1002/path.6291 http://creativecommons.org/licenses/by/4.0/ |
| title | PCDHGC3 hypermethylation as a potential biomarker of intestinal neuroendocrine carcinomas |
| topic | The Journal of Pathology |
| url | https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6291 |